Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (ABT +1.28%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott facts
|
Headquarters (founded) |
Abbott Park, Ill. (1888) |
|
Market Cap |
$58.9 billion |
|
Industry |
Health care equipment |
|
Trailing-12-Month Revenue |
$40 billion |
|
Management |
Chairman/CEO Miles White (since 1999) |
|
Return on Equity (average, past 3 years) |
20.6% |
|
Cash / Debt |
$8.5 billion / $7.1 billion |
|
Dividend Yield |
1.5% |
|
Competitors |
Boston Scientific |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,617 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, cschweit, succinctly summed up the Abbott bull case for our community:
Undervalued stock as of right now. Biggest growth will come from emerging markets. Will need to deliver to those emerging markets if it will succeed -- which I think it can. A little worried about a major buyout of its major branches. ... Still a strong company with a good future.
